News & Events
News & Events
October 28, 2011
C-Path’s Avilés Discusses Importance of Data Standards in FDA Week ArticleFDA is encouraging industry to use newly crafted therapeutic data standards — such as utilization of qualified biomarkers– in submissions and could start requiring companies to use the standardized data elements in the future,sources said following the release of the first set of standardized therapeutic data elements for Alzheimer’s disease that they said could make...
October 17, 2011
Critical Path Institute and Clinical Data Interchange Standards Consortium Announce Release of Data Standards for Alzheimer’s Disease ResearchCritical Path Institute(C-Path)and Clinical Data Interchange Standards Consortium(CDISC) today announced the release of version 1.0 of the Alzheimer’s disease (AD) Therapeutic Area Standard(SDTM AD/Mild Cognitive Impairment User Guide). This was developed for the clinical research community to facilitate analysis and learning from clinical studies for treatment or prevention of AD.
October 1, 2011
C-Path’s K. Romero Co-Authors Special Report- Striving for an Integrated Drug-Development Process for Neurodegeneration: the Coalition Against Major DiseasesAlzheimer’s and Parkinson’s diseases are the two main neurodegenerative disorders and despite the public health need, drug development for these conditions has been plagued by a high attrition rate in the late phases of evaluation.
September 16, 2011
Critical Path Institute Announces Launch of Critical Path FoundationFoundation to foster a global community of philanthropists to improve health and save lives
September 7, 2011
Pharsight to Work with Critical Path Institute’s Polycystic Kidney Disease Consortium on Disease Progression ModelingPharsight, a market-leading provider of software and scientific consulting services to improve productivity and decisionmaking in clinical drug development, has announced they will be working with Critical Path Institute’s Polycystic Kidney Disease (PKD) Consortium to create and study quantitative models of disease progression in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD).